{
    "data": [
        {
            "id": "urn:summary_document_transcript:quartr.com:2940228:0",
            "title": "Definium Therapeutics Inc: Three pivotal Phase 3 readouts for DT120 ODT expected in 2026, with strong financial position",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Advanced late-stage pipeline with three pivotal Phase 3 readouts for DT120 ODT in GAD and MDD expected in 2026, supported by a strong cash position and commercial readiness. R&amp;D and G&amp;A expenses rose significantly, with net loss impacted by warrant revaluation. Cash runway extends into 2028.</span></p><p class=\"\"><span>Based on Definium Therapeutics Inc Q4 2025 Audio Transcript — Feb. 26 2026</span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940228:0-definium-therapeutics-inc-three-pivotal-phase-3-readouts-for-dt120-odt-expected-in-2026-with-strong-financial-position/",
            "pub_date": "2026-02-27 07:23:10",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940230:0",
            "title": "SNDX: 2025 revenue hit $172.4M, with both Revuforj and Niktimvo outperforming launch expectations",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Revenue reached $172.4M in 2025, driven by strong launches of Revuforj and Niktimvo, both exceeding benchmarks. Robust growth, expanding indications, and a solid balance sheet position the company for profitability and continued pipeline advancement.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940230:0-sndx-2025-revenue-hit-172-4m-with-both-revuforj-and-niktimvo-outperforming-launch-expectations/",
            "pub_date": "2026-02-27 07:23:12",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940231:0",
            "title": "CRNX: Breakout 2025 with PALSONIFY launch, pipeline advances, and strong cash position for future growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>2025 marked a pivotal year with the successful U.S. launch of PALSONIFY, strong financial discipline, and robust pipeline progress, including positive EU regulatory momentum and new clinical trial initiations. Cash reserves and guidance support operations into 2030.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940231:0-crnx-breakout-2025-with-palsonify-launch-pipeline-advances-and-strong-cash-position-for-future-growth/",
            "pub_date": "2026-02-27 07:23:14",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940232:0",
            "title": "KIDS: Q4 2025 delivered record revenue growth, margin expansion, and first-ever positive free cash flow",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw 17% revenue growth, improved margins, and the first positive free cash flow, driven by strong performance across all segments and major product launches. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and free cash flow breakeven.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940232:0-kids-q4-2025-delivered-record-revenue-growth-margin-expansion-and-first-ever-positive-free-cash-flow/",
            "pub_date": "2026-02-27 07:23:15",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940233:0",
            "title": "PAR: Q4 saw double-digit revenue growth, record ARR, and accelerating AI-driven platform adoption",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 revenue rose 14% year-over-year to $120.1M, with record ARR growth and strong subscription momentum. AI-driven products and multiproduct deals fueled performance, while supply chain pressures impacted hardware margins. 2026 guidance calls for mid-teens ARR growth and improved margins.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940233:0-par-q4-saw-double-digit-revenue-growth-record-arr-and-accelerating-ai-driven-platform-adoption/",
            "pub_date": "2026-02-27 07:23:17",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940234:0",
            "title": "BDSX: Q4 delivered 41% revenue growth and first positive adjusted EBITDA, with 2026 guidance up 23%",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Q4 2025 saw 41% revenue growth and first-ever positive adjusted EBITDA, driven by lung diagnostics and expanded sales reach. 2026 guidance projects 23% revenue growth, with continued margin strength and operational leverage. Cash position strengthened by new financing and loan extension.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940234:0-bdsx-q4-delivered-41-revenue-growth-and-first-positive-adjusted-ebitda-with-2026-guidance-up-23/",
            "pub_date": "2026-02-27 07:23:17",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KS:0",
            "title": "Autodesk Inc reports results for the quarter ended January 31 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc </span><span> reported quarterly adjusted earnings of $2.67​​ per share for the quarter ended January 31, higher than the same quarter last year, when the company reported EPS of $2.29.  The mean expectation of twenty four analysts for the quarter was for earnings of $2.64 per share. Wall Street expected results to range from $2.48  to $2.77 per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue rose 18% to $1.85 billion from a year ago; analysts expected $1.91 billion. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc's reported EPS for the quarter was $1.60​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $316 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Autodesk Inc shares had fallen by 24.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts was unchanged in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 29 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the software peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Autodesk Inc is $365.00, about 36% above its last closing price of $233.45</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Oct. 31 2025 </span></p></td><td><p class=\"\"><span>2.50</span></p></td><td><p class=\"\"><span>2.85</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jul. 31 2025 </span></p></td><td><p class=\"\"><span>2.45</span></p></td><td><p class=\"\"><span>2.67</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Apr. 30 2025 </span></p></td><td><p class=\"\"><span>2.45</span></p></td><td><p class=\"\"><span>2.62</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jan. 31 2025 </span></p></td><td><p class=\"\"><span>2.14</span></p></td><td><p class=\"\"><span>2.29</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KS:0-autodesk-inc-reports-results-for-the-quarter-ended-january-31-earnings-summary/",
            "pub_date": "2026-02-27 07:23:24",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZM2P5:0",
            "title": "Singapore's Olam Group annual profit jumps more than five-fold",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Singapore's Olam Group </span><span> reported a more than five-fold jump in annual profit on Friday, helped by strong performance across its businesses.</span></p><p class=\"\"><span>Olam, one of the world's biggest agricultural commodities traders, posted profit attributable of S$444.1 million ($351.34 million) for the year ended December 31, compared with S$86.4 million last year.</span></p><p class=\"\"><span>($1 = 1.2640 Singapore dollars)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZM2P5:0-singapore-s-olam-group-annual-profit-jumps-more-than-five-fold/",
            "pub_date": "2026-02-27 07:24:06",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KZ:0",
            "title": "Emergent BioSolutions Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc </span><span> reported quarterly adjusted earnings of $1.06​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $1.37.  The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. to range from -35 cents to 11 cents per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 23.6% to $231.10 million from a year ago; analysts expected $194.00 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc's reported EPS for the quarter was a loss of $1.04​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported a quarterly loss of $54.6 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Emergent BioSolutions Inc shares had fallen by 10.9% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 191.7% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 17.8% above its last closing price of $11.10</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:24 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>0.11</span></p></td><td><p class=\"\"><span>1.06</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.12</span></p></td><td><p class=\"\"><span>1.06</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.49</span></p></td><td><p class=\"\"><span>0.71</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2024 </span></p></td><td><p class=\"\"><span>0.44</span></p></td><td><p class=\"\"><span>0.05</span></p></td><td><p class=\"\"><span>Missed</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KZ:0-emergent-biosolutions-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:24:28",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM1Q6:0",
            "title": "Bain Capital Specialty Finance Q4 net income per share rises q-o-q",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Specialty finance firm's Q4 net investment income per share was $0.46</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Net income per share for Q4  was $0.43</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company declares first-quarter 2026 dividend of $0.42 per share</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>STRONG NET INVESTMENT INCOME - BCSF's net investment income per share was $0.46, covering dividends, driven by stable credit metrics and low non-accruals</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Q4 EPS</span></p></td></tr><tr><td><p class=\"\"><span>Beat/Miss</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>$0.43</span></p></td></tr><tr><td><p class=\"\"><span>Consensus Estimate</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The average consensus recommendation for the investment management &amp; fund operators peer group is \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Bain Capital Specialty Finance Inc is $14.50, about 13.7% above its February 26 closing price of $12.75</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM1Q6:0-bain-capital-specialty-finance-q4-net-income-per-share-rises-q-o-q/",
            "pub_date": "2026-02-27 07:24:40",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_slides:quartr.com:2940240:0",
            "title": "BCO: Merger forms a $10B revenue fintech leader, targeting $200M synergies and strong EPS growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>A merger will create a financial technology infrastructure leader with ~$10B revenue and ~$2B adjusted EBITDA, targeting $200M in annual cost synergies and strong free cash flow. The deal is expected to be 35% EPS accretive and close in Q1 2027, with a focus on growth, margin expansion, and shareholder value.</span></p><p class=\"\"><span>Original document: </span><a class=\"link-zw5jRdec\" href=\"https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A2940240-00b6bc94d8f92ee72579c81b9cd63037\" target=\"_blank\">Brinks Company (The) [BCO] Slides Release — Feb. 26 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:2940240:0-bco-merger-forms-a-10b-revenue-fintech-leader-targeting-200m-synergies-and-strong-eps-growth/",
            "pub_date": "2026-02-27 07:24:40",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZM1QN:0",
            "title": "Aura Minerals Q4 net revenue surges on higher gold, copper prices",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Overview</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Canada-based gold miner's Q4 net revenue rose 88% YoY</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Adjusted EBITDA for Q4 hit record high, driven by higher production and metal prices</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company completed acquisition of MSG Gold Mine in December 2025</span></p></li></ul><p class=\"\"><span>Outlook</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Aura projects 2026 production to grow to 360,000–390,000 GEO</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Company aims to exceed 600,000 GEO annually in coming years</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Aura plans capacity expansions at Borborema and Almas</span></p></li></ul><p class=\"\"><span>Result Drivers</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>HIGHER PRODUCTION - Aura's Q4 2025 production increased 23% YoY, driven by Borborema ramp-up and MSG acquisition</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>HIGHER METAL PRICES - Q4 2025 net revenue rose 88% YoY, aided by higher gold and copper prices</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>STABLE COSTS - Aura maintained stable costs, contributing to record Adjusted EBITDA in Q4 2025</span></p></li></ul><p class=\"\"><span>Company press release: </span></p><p class=\"\"><span>Key Details</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Metric</span></p></td><td><p class=\"\"><span>Q4 Revenue</span></p></td></tr><tr><td><p class=\"\"><span>Beat/Miss</span></p></td><td><p class=\"\"><span>Slight Miss*</span></p></td></tr><tr><td><p class=\"\"><span>Actual</span></p></td><td><p class=\"\"><span>$321.60 mln</span></p></td></tr><tr><td><p class=\"\"><span>Consensus Estimate</span></p></td><td><p class=\"\"><span>$324.45 mln (2 Analysts)</span></p></td></tr></tbody></table></div><p class=\"\"><span>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</span></p><p class=\"\"><span>Analyst Coverage</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Aura Minerals Inc is $75.00, about 16.4% below its February 26 closing price of $89.74</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 8 three months ago</span></p></li></ul><p class=\"\"><span>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:reuters.support@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">reuters.support@thomsonreuters.com</a><span>.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZM1QN:0-aura-minerals-q4-net-revenue-surges-on-higher-gold-copper-prices/",
            "pub_date": "2026-02-27 07:24:55",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018918:0",
            "title": "Netflix to Invest $20B Content After Ceding Warner to Paramount — Market Talk",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Netflix is doubling down on its own content after declining to up the ante in a bidding war with Paramount for Warner Bros. Discovery. Netflix invest about $20 billion in quality films and series this year and expand its entertaining offering, and also plans to resume its share buyback program. The company had signed a deal for Warner's studios and HBO Max for $72 billion. The deal was \"a 'nice to have' at the right price, not a 'must have' at any price,\" Netflix's co-CEOs say in a statement. \"Netflix's business is healthy, strong and growing organically, powered by our slate and best-in-class streaming service.\" (kelly.cloonan@wsj.com)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018918:0/",
            "pub_date": "2026-02-27 07:25:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "urn:summary_document_transcript:quartr.com:2940201:0",
            "title": "QSR: Clear roadmap to 5%+ net restaurant growth and double-digit shareholder returns by 2028",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Management outlined a clear path to 5%+ net restaurant growth and 8% AOI growth by 2028, driven by international expansion, operational improvements, and disciplined capital allocation. Franchisee alignment, technology innovation, and refranchising are central to the strategy, with investment-grade leverage and increased shareholder returns targeted.</span></p><p class=\"\"><span>Based on </span></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:2940201:0-qsr-clear-roadmap-to-5-net-restaurant-growth-and-double-digit-shareholder-returns-by-2028/",
            "pub_date": "2026-02-27 07:17:36",
            "source": "Quartr",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KF:0",
            "title": "BioLife Solutions Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc </span><span> reported quarterly adjusted earnings of 22 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -4 cents.  The mean expectation of ten analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to 1 cents per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 19% to $24.76 million from a year ago; analysts expected $24.08 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc's reported EPS for the quarter was 1 cent​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $11.07 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>BioLife Solutions Inc shares had fallen by 7.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 30% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, three analysts negatively revised earnings estimates</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for BioLife Solutions Inc is $32.00, about 29.8% above its last closing price of $22.48</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>0.22</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.04</span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-0.05</span></p></td><td><p class=\"\"><span>-0.01</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.05</span></p></td><td><p class=\"\"><span>0.26</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KF:0-biolife-solutions-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:17:41",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_TUA5BRHS0:0",
            "title": "Ginkgo Bioworks Reports Fourth Quarter And Full Year 2025 Financial Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Ginkgo Bioworks Holdings Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>GINKGO BIOWORKS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS, ANNOUNCES FOCUS ON AUTONOMOUS LABS OFFERINGS AND DIVESTITURE OF ITS NON-CORE BIOSECURITY BUSINESS</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA5BRHS0:0-ginkgo-bioworks-reports-fourth-quarter-and-full-year-2025-financial-results/",
            "pub_date": "2026-02-27 07:17:42",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KG:0",
            "title": "Puma Biotechnology Inc reports results for the quarter ended September 30 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc </span><span> reported quarterly adjusted earnings of 26 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 41 cents.  The lone analyst forecast for the quarter was for earnings of 23 cents per share. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 6.2% to $75.50 million from a year ago; analysts expected $51.00 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc's reported EPS for the quarter was 26 cents​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $8.8 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Puma Biotechnology Inc shares had risen by 29.1% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had risen by about 404.4% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, two analysts negatively revised earnings estimates</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is no \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the pharmaceuticals peer group is  \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Puma Biotechnology Inc is $5.00, about 52% below its last closing price of $7.60</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2025 </span></p></td><td><p class=\"\"><span>0.23</span></p></td><td><p class=\"\"><span>0.26</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>0.10</span></p></td><td><p class=\"\"><span>0.17</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-0.02</span></p></td><td><p class=\"\"><span>0.12</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>0.10</span></p></td><td><p class=\"\"><span>0.39</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KG:0-puma-biotechnology-inc-reports-results-for-the-quarter-ended-september-30-earnings-summary/",
            "pub_date": "2026-02-27 07:17:43",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018880_20260226018880:0",
            "title": "Shenzhen Zhaowei Machinery & Electronics Looks to Raise HK$1.97B in Hong Kong Offering",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018880_20260226018880:0/",
            "pub_date": "2026-02-27 07:18:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018821_20260226018882:0",
            "title": "Olam Group: ofi Maintains Existing Guidance for Low- to Mid-Single Digit Total Volume Growth, High Single-Digit Adjusted EBIT Growth Over Medium-Term >S63.SG",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018821_20260226018882:0/",
            "pub_date": "2026-02-27 07:18:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM279:0",
            "title": "Sidus Space May Offer & Sell Shares Of Class A Common Stock From Time To Time, Offering Price Of Up To $100 Million",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Sidus Space Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>SIDUS SPACE INC MAY OFFER &amp; SELL SHARES OF CLASS A COMMON STOCK FROM TIME TO TIME, OFFERING PRICE OF UP TO $100 MILLION- SEC FILING</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM279:0-sidus-space-may-offer-sell-shares-of-class-a-common-stock-from-time-to-time-offering-price-of-up-to-100-million/",
            "pub_date": "2026-02-27 07:18:09",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM290:0",
            "title": "Molina Healthcare Reaffirms 2026 Adjusted EPS Guidance",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Molina Healthcare Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>MOLINA HEALTHCARE - REAFFIRMS 2026 ADJUSTED EPS GUIDANCE AT LEAST $5.00  - SEC FILING</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM290:0-molina-healthcare-reaffirms-2026-adjusted-eps-guidance/",
            "pub_date": "2026-02-27 07:18:32",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018880_20260226018885:0",
            "title": "Shenzhen Zhaowei Machinery to Offer 26,748,300 Shrs at Maximum Price of HK$73.68 Each",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018880_20260226018885:0/",
            "pub_date": "2026-02-27 07:19:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018884:0",
            "title": "OpenAI Tells Canada It Will Strengthen Safety Protocols After Mass Shooting Left Eight Dead",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>By Paul Vieira</span></p><p class=\"\"><span>OTTAWA--OpenAI made a series of pledges Thursday to Canadian officials to bolster safety protocols following the fatal shooting in British Columbia in which the suspect interacted with its chatbot.</span></p><p class=\"\"><span>The company said it would have more flexible criteria under which accounts are referred to law enforcement agencies. Further, it said it would establish direct points of contact with Canadian law-enforcement officials, help direct users in distress to relevant local support agencies, and toughen its detection system to prevent attempts to evade safeguards.</span></p><p class=\"\"><span>\"These immediate commitments are only the first step in the work we must do in partnership with the Canadian government to improve AI safety,\" said Ann O'Leary, vice-president of global policy at OpenAI. \"With the benefit of our continued learnings, under our enhanced law enforcement referral protocol, we would refer the account banned in June 2025 to law enforcement if it were discovered today.\"</span></p><p class=\"\"><span>The pledges come after OpenAI executives met with senior Canadian officials this week. Police have identified Jesse Van Rootselaar as the suspect in a fatal shooting at a school in Tumbler Ridge, British Columbia this month that killed eight people and left dozens injured. Police said Van Rootselaar was found dead from what appeared to be a self-inflicted injury at the school scene.</span></p><p class=\"\"><span>The Wall Street Journal reported last week that OpenAI considered alerting Canadian law enforcement authorities about interactions between Van Rootselaar and ChatGPT. Some OpenAI employees worried the suspect's writings were a warning about potential real-world violence, the Journal reported.</span></p><p class=\"\"><span>OpenAI shut down Van Rootselaar's ChatGPT account in June after detecting a violation of its policy, but did not notify police.</span></p><p class=\"\"><span>Write to Paul Vieira at paul.vieira@wsj.com</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018884:0/",
            "pub_date": "2026-02-27 07:19:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KO:0",
            "title": "Ducommun Inc reports results for the quarter ended December 31 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ducommun Inc </span><span> reported quarterly adjusted earnings of $1.05​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of 75 cents.  The mean expectation of five analysts for the quarter was for earnings of 96 cents per share. Wall Street expected results to range from 91 cents to $1.03 per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue rose 9.4% to $215.80 million from a year ago; analysts expected $221.00 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ducommun Inc's reported EPS for the quarter was 48 cents​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported quarterly net income of $7.44 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ducommun Inc shares had risen by 33.3% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, one analyst negatively revised an earnings estimate</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" The average consensus recommendation for the aerospace &amp; defense peer group is also \"buy\" </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Ducommun Inc is $127.00, about 3.6% above its last closing price of $122.40</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Dec. 31 2025 </span></p></td><td><p class=\"\"><span>0.96</span></p></td><td><p class=\"\"><span>1.05</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>0.95</span></p></td><td><p class=\"\"><span>0.99</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>0.82</span></p></td><td><p class=\"\"><span>0.88</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>0.70</span></p></td><td><p class=\"\"><span>0.83</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KO:0-ducommun-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/",
            "pub_date": "2026-02-27 07:19:27",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_TUABW2MKL:0",
            "title": "Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Pacira Biosciences Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACIRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACIRA BIOSCIENCES FY ADJUSTED EBITDA USD 186.5 MILLION VS. IBES ESTIMATE USD 204 MILLION</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACIRA BIOSCIENCES FY NET INCOME USD 7 MILLION</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACIRA BIOSCIENCES FY ADJUSTED NET INCOME USD 122.3 MILLION VS. IBES ESTIMATE USD 139.8 MILLION</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>PACIRA BIOSCIENCES INC - OUTLOOK 2026 TOTAL REVENUE OF $745 MILLION TO $770 MLN</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUABW2MKL:0-pacira-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results/",
            "pub_date": "2026-02-27 07:20:26",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018845_20260226018845:0",
            "title": "NextDC Target Price Cut 9.5% to A$20.40/Share by Canaccord Genuity>NXT.AU",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018845_20260226018845:0/",
            "pub_date": "2026-02-27 07:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260226018846:0",
            "title": "Block Plans to Ramp Up AI Spending Following Job Cuts — Market Talk",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Block plans to hire more senior AI-engineering talent after it cuts 4,000 of its current workers, Chief Financial Officer Amrita Ahuja tells analysts on a call. The goal is to improve the company's engineering and product capabilities, Ahuja says. Block is also investing more in AI infrastructure and continuing to spend more in go-to-market to scale customer-acquisition efforts, she says. Ahuja says margins are expected to increase over the course of this fiscal year, but won't show up in the first quarter, as costs related to the job cuts will still be trickling through. (katherine.hamilton@wsj.com)</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260226018846:0/",
            "pub_date": "2026-02-27 07:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_TUA7Q4HY:0",
            "title": "Duos Technologies Group Announces Proposed Public Offering Of Common Stock",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Duos Technologies Group Inc </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>DUOS TECHNOLOGIES GROUP, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>DUOS TECHNOLOGIES GROUP INC - PROCEEDS TO EXPAND EDGE DATA CENTER BUSINESS</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA7Q4HY:0-duos-technologies-group-announces-proposed-public-offering-of-common-stock/",
            "pub_date": "2026-02-27 07:14:07",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L8N3ZM3KD:0",
            "title": "Ginkgo Bioworks Holdings Inc reports results for the quarter ended December 31 - Earnings Summary",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ginkgo Bioworks Holdings Inc </span><span> reported a quarterly adjusted loss of $1.41​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.00.  The mean expectation of three analysts for the quarter was for a loss of $1.24 per share. Wall Street expected results to range from $-1.27 to $-1.11 per share.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Revenue fell 56.4% to $33.40 million from a year ago; analysts expected $37.09 million. </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $1.45​.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company reported a quarterly loss of $80.75 million.</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Ginkgo Bioworks Holdings Inc shares had risen by 12.9% this quarter.</span></p></li></ul><p class=\"\"><span>FORECAST CHANGES</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The mean earnings estimate of analysts had fallen by about 17.3% in the last three months.​ </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>In the last 30 days, one analyst negatively revised an earnings estimate</span></p></li></ul><p class=\"\"><span>RECOMMENDATIONS</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The current average analyst rating on the shares is \"sell\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and 3 \"sell\" or \"strong sell.\" The average consensus recommendation for the biotechnology &amp; medical research peer group is  \"buy.\"</span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $9.00, about 7.9% below its last closing price of $9.71</span></p></li></ul><p class=\"\"><span>This summary was machine generated from LSEG data February 26 at 11:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:RefinitivNewsSupport@thomsonreuters.com\" rel=\"nofollow\" target=\"_blank\">RefinitivNewsSupport@thomsonreuters.com</a><span>)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>QUARTER ENDING</span></p></td><td><p class=\"\"><span>ESTIMATE </span></p></td><td><p class=\"\"><span>ACTUAL</span></p></td><td><p class=\"\"><span>BEAT, MET, MISSED</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>-1.45</span></p></td><td><p class=\"\"><span>-1.41</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Sep. 30 2025 </span></p></td><td><p class=\"\"><span>-1.57</span></p></td><td><p class=\"\"><span>-1.45</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Jun. 30 2025 </span></p></td><td><p class=\"\"><span>-1.57</span></p></td><td><p class=\"\"><span>-1.10</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr><tr><td><p class=\"\"><span>Mar. 31 2025 </span></p></td><td><p class=\"\"><span>-1.77</span></p></td><td><p class=\"\"><span>-1.68</span></p></td><td><p class=\"\"><span>Beat</span></p></td></tr></tbody></table></div></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N3ZM3KD:0-ginkgo-bioworks-holdings-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/",
            "pub_date": "2026-02-27 07:14:27",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_FWN3ZM2BU:0",
            "title": "Rli Corp Files Final Term Sheet For Offering Of $300 Million 5.375% Senior Notes Due 2036",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Rli Corp </span><span>:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>RLI CORP FILES FINAL TERM SHEET FOR OFFERING OF $300 MILLION 5.375% SENIOR NOTES DUE 2036 - SEC FILING</span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN3ZM2BU:0-rli-corp-files-final-term-sheet-for-offering-of-300-million-5-375-senior-notes-due-2036/",
            "pub_date": "2026-02-27 07:14:29",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        }
    ]
}